Elevance Health Grows Revenue 12%, Invests for Future While Managing Margin Pressures in Q3 2025

Revenue Growth Outpaces Market—Driven by Premium Yields and Acquisitions

In the third quarter of 2025, Elevance Health delivered operating revenue of $50.1 billion, representing a 12% increase over the same quarter last year. This top-line growth was fueled by stronger premium yields in the Health Benefits segment, recent acquisitions, and expansion in Medicare Advantage membership. Notably, the Carelon segment also posted a 33% year-over-year jump in revenue as recent acquisitions in home health and pharmacy services took hold.

Growth was strongest in the Carelon Services sub-segment, where operating revenue climbed 57.9% year-over-year for the quarter. In contrast, the Health Benefits segment's operating revenue grew by a healthy 10.4%, but ongoing Medicaid membership reverifications tempered some of the upside.

Margin Pressures and Strategic Investments Shape Profitability

Despite the robust revenue growth, Elevance Health's margins compressed versus the prior year. The consolidated operating margin declined to 2.6% from 3.1% in Q3 2024, with the Health Benefits segment dropping from 4.2% to 1.4%—largely attributed to elevated medical cost trends and increased investments to advance technology and workforce capabilities.

The company noted its benefit expense ratio increased to 91.3%, up 180 basis points year-over-year, primarily from expected Medicare cost trends and seasonality in Part D benefits. Meanwhile, the operating expense ratio improved to 10.5%, a 130-basis-point improvement, even as Elevance Health increased spending on key strategic initiatives like scaling Carelon and technology transformation.

Membership Growth Mixed as Medicare Advantage Expands

Medical membership at quarter-end was approximately 45.4 million, down 0.9% from last year, driven mainly by lower BlueCard® and Medicaid membership amid reverifications. Medicare Advantage membership, however, surged 9.7% to 2.25 million, reinforcing the company’s ongoing pivot to this growth area. CarelonRx processed 85.0 million quarterly scripts (up 6%), and Carelon Services reached 97.6 million consumers, slightly below the previous year.

Capital Returns Remain Steady—Repurchases and Dividends Ongoing

Elevance Health continues to prioritize returning capital to shareholders, with $3.3 billion returned year-to-date. In Q3, the company repurchased 2.9 million shares for $875 million (at a weighted average price of $303.48) and paid a quarterly dividend of $1.71 per share. $7.2 billion remains available under the current Board-approved buyback authorization.

Balance Sheet Strength Supports Ongoing Investment

The company ended Q3 with $8.7 billion in cash and cash equivalents and $2.6 billion in parent company cash and investments. While year-to-date operating cash flow decreased to $4.2 billion (0.8x net income) partly due to a litigation settlement payment, overall financial flexibility remains sound. Debt levels are steady, and the company continues to invest in workforce, technology, and integration of recent acquisitions.

2025 Outlook Reaffirmed—Benefit Expense and Adjusted EPS Targets Hold

Looking ahead, Elevance Health reaffirmed its full-year 2025 guidance for a benefit expense ratio of approximately 90.0% and adjusted diluted EPS of about $30.00. This reflects management's confidence in the company’s underlying growth, expense discipline, and ability to absorb current cost trends.

Takeaway: Growth Investments Position Elevance Health for the Long Term

While short-term margin compression and membership churn present challenges, Elevance Health’s strategic priorities remain intact. Strong revenue growth, rising Medicare Advantage membership, and sustained capital returns offer stability. With the ongoing push into value-based care, digital solutions, and integration of recent acquisitions, the company appears poised to weather industry headwinds and capitalize on evolving healthcare demand in the years ahead.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI